EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia

Christoph Röllig iD, Björn Steffen, Christoph Schliemann iD, Jan-Henrik Mikesch, Nael Alakel iD, Regina Herbst, Mathias Hänel, Richard Noppeney, Maher Hanoun, Martin Kaufmann, Barbora Weinbergerova iD, Kerstin Schäfer-Eckart und 32 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco.24.00235 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Christoph Röllig und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany. Hauptthemen laut MEDLINE: Daunorubicin, Leukemia, Myeloid, Acute, Cytarabine, Induction Chemotherapy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m 2 with 90 mg/m 2 daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction. PATIENTS AND METHODS Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m 2 daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle. RESULTS Eight hundred and sixty-four patients with a median age of 52 years were randomly assigned. After a preplanned interim analysis showing no significant difference in response between 60 and 90 mg/m 2 , all consecutive patients received 60 mg/m 2 daunorubicin once daily. The proportion of good early responders was 44% versus 48% ( P = .983) with a composite complete remission (CRc) rate of 90% versus 89% after induction ( P = .691); the 3-year relapse-free survival (RFS) after 60 versus 90 mg/m 2 once daily was 54% versus 50% ( P = .561), and the 3-year overall survival (OS) was 65% versus 58% ( P = .242). Among 389 good responders, CRc rates at the end of induction were 87% after single induction and 85% after double induction. The 3-year RFS was 51% versus 60% (hazard ratio [HR], 1.3; P = .091), and the 3-year OS was 76% versus 75% after single versus double induction (HR, 1.0; P = .937). CONCLUSION The use of 90 mg/m 2 daunorubicin once daily in the context of classical 7 + 3 induction does not significantly improve early response and does not lead to higher remission rates or longer survival than 60 mg/m 2 once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DaunorubicinLeukemia, Myeloid, AcuteCytarabineInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedAdultMaleFemaleAgedYoung AdultRemission InductionAdolescentDrug Administration ScheduleAntibiotics, Antineoplastic

Substanzen

DaunorubicinCytarabineAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
  • Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany.
  • Department of Medicine A, University Hospital Münster, Münster, Germany.
  • Department of Internal Medicine III, Chemnitz Hospital, Chemnitz, Germany.
  • Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Hematology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.

ORCID-Profile: Christoph Röllig, Christoph Schliemann, Nael Alakel, Barbora Weinbergerova, Tim Sauer, Andreas Neubauer, Andreas Burchert, Stefan W Krause, Andreas Hochhaus, Tomas Szotkowski, Christoph Schmid, Lars Fransecky, Johannes Schetelig, Jan Moritz Middeke, Uwe Platzbecker, Christian Thiede, Carsten Müller-Tidow, Wolfgang E Berdel, Jiri Mayer, Hubert Serve, Martin Bornhäuser

Zitieren

APA

Röllig, C., Steffen, B., Schliemann, C., Mikesch, J. H., Alakel, N., Herbst, R., Hänel, M., Noppeney, R., Hanoun, M., Kaufmann, M., Weinbergerova, B., Schäfer-Eckart, K., Sauer, T., Neubauer, A., Burchert, A., Baldus, C. D., Mertová, J., Jost, E., Niemann, D., …, & Bornhäuser, M. (2025). Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00235

Vancouver

Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, et al. Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. Journal of Clinical Oncology. 2025. doi:10.1200/jco.24.00235

BibTeX
@article{Rllig2025,
  author = {Röllig, Christoph and Steffen, Björn and Schliemann, Christoph and Mikesch, Jan-Henrik and Alakel, Nael and Herbst, Regina and Hänel, Mathias and Noppeney, Richard and Hanoun, Maher and Kaufmann, Martin and Weinbergerova, Barbora and Schäfer-Eckart, Kerstin and Sauer, Tim and Neubauer, Andreas and Burchert, Andreas and Baldus, Claudia D and Mertová, Jolana and Jost, Edgar and Niemann, Dirk and Novák, Jan and Krause, Stefan W and Scholl, Sebastian and Hochhaus, Andreas and Held, Gerhard and Szotkowski, Tomas and Rank, Andreas and Schmid, Christoph and Fransecky, Lars and Kayser, Sabine and Schaich, Markus and Kramer, Michael and Fiebig, Frank and Haake, Annett and Schetelig, Johannes and Middeke, Jan Moritz and Stölzel, Friedrich and Platzbecker, Uwe and Thiede, Christian and Müller-Tidow, Carsten and Berdel, Wolfgang E and Ehninger, Gerhard and Mayer, Jiri and Serve, Hubert and Bornhäuser, Martin},
  title = {Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco.24.00235}
}
Kostenlos starten →